Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galicaftor/navocaftor/ABBV-119 combination therapy in adults with cystic fibrosis
ISRCTN48897533Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jul 2021
- Modality
- Small Molecules
01
Overview
Phase 2, randomised trial of galicaftor, navocaftor and ABBV-119 in cystic fibrosis (CF) (4 arms), sponsored by AbbVie Inc. Primary endpoint: Absolute change from baseline through Day 29 in percent predicted forced expiratory volume in 1 second. Started Jul 2021; status: terminated.
02
Drugs
galicaftornavocaftorABBV-119
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on ISRCTN48897533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN48897533.